Abstracts

623 – Ten-Year Cancer Survival Rate in an Italian Cohort of People With HIV From 2008 to 2025

Background People with HIV (PWH) are at increased risk of developing malignancies. This study aimed to estimate long term survival rates in PWH diagnosed with cancer, stratified by virus-related cancer (VRC; anal and invasive cervical cancer, hepatocellular carcinoma, Kaposi sarcoma, Hodgkin and non-Hodgkin lymphoma) and non–virus-related cancer (NVRC).  Methods We included PWH with a VRC…

625 – Kaposi Sarcoma, With and Without Pulmonary Involvement: Clinical Differences and Outcomes

Background Kaposi sarcoma (KS) is caused by human herpes 8 virus (HHV8); immunosuppression and inflammatory cytokines play a major role in its pathogenesis. We aimed to describe the clinical differences and outcomes of patients with disseminated KS, with and without pulmonary involvement. Methods We conducted a single-center retrospective cohort study from 2018 to 2024, including…

740 – Pemivibart for Prevention of COVID-19: Phase III CANOPY Subset in Advanced HIV Infection

Background People living with HIV remain at increased risk of severe outcomes from COVID-19 due to underlying immunologic vulnerability and comorbidities. Pemivibart is a recombinant human monoclonal IgG1λ antibody that targets the SARS-CoV-2 spike protein receptor binding domain, thereby inhibiting virus attachment to host cells. Based on Phase 3 CANOPY data (NCT06039449), pemivibart was granted emergency…

235 – 5’Leader Defective HIV-1 Proviruses From PWH With Nonsuppressible Viremia Produce Soluble gp120

Background Antiretroviral therapy (ART) blocks HIV-1 replication, yet some people with HIV (PWH) develop non-suppressible viremia (NSV). Clonally expanded infected CD4+ T cells, harboring defects in the 5’Leader region (5’L), contribute to persistent viremia in PWH with NSV. Production of viral proteins from these defective proviruses may drive immune dysfunction during ART. We recently observed…

517 – Patient-Reported Outcomes After 52 Weeks of Twice-Yearly Lenacapavir, Teropavimab, and Zinlirvimab

Background Lenacapavir (LEN), an HIV-1 capsid inhibitor, combined with broadly neutralizing antibodies teropavimab (TAB) and zinlirvimab (ZAB) is under investigation as a twice-yearly (Q6M) HIV-1 treatment in a Phase 2 open-label study (NCT05729568). We describe W52 patient-reported outcomes (PROs) for treatment preference/satisfaction, and health-related quality of life (HRQoL).  Methods This study enrolled virologically suppressed (HIV-1…

525 – Early Switch to CAB+RPV LA in Treatment-Naive Adults With HIV-1: Month 11 Outcomes From VOLITION

Background Long-acting cabotegravir+rilpivirine (CAB+RPV LA) and dolutegravir/lamivudine (DTG/3TC) are INSTI–based, antiretroviral therapy (ART) regimens with different indications, modalities, and dosing schedules. VOLITION (NCT05917509) is the first study to evaluate optional switch to CAB+RPV LA, based on participant choice, immediately after attaining virologic suppression with DTG/3TC in ART-naive adults with HIV-1. Median time to suppression on DTG/3TC…

851 – Pharmacokinetics of a Novel Dose Ratio of DTG/FTC/TAF for African Children With HIV (UNIVERSAL1)

Background To accelerate development of pediatric antiretroviral formulations for children, the WHO-led Paediatric Antiretroviral Drug Optimization group regularly reviews priorities for drug development. High on this priority list is a dispersible fixed dose combination of dolutegravir (DTG), emtricitabine (FTC) and tenofovir alafenamide fumarate (TAF) for treatment of ART naïve and experienced children living with HIV. The optimal dose ratio for this novel DTG/FTC/TAF pediatric tablet is 5/15/1.88 mg…

879 – Impact of PrEP on HIV-1 Diversity & Drug Resistance in Newly Diagnosed Patients in Málaga, 2016-2023

Background In late 2019, pre-exposure prophylaxis (PrEP) for HIV infection was approved in Spain, potentially altering HIV-1 molecular epidemiology and reducing the number of new infections within transmission chains (TCs). We aimed to analyze the presence and characteristics of TCs in newly diagnosed HIV-1 patients before and after PrEP implementation, and to assess the prevalence…